首页> 美国卫生研究院文献>Pharmaceutics >Modeling and Simulation of Process Technology for Nanoparticulate Drug Formulations—A Particle Technology Perspective
【2h】

Modeling and Simulation of Process Technology for Nanoparticulate Drug Formulations—A Particle Technology Perspective

机译:纳米颗粒药物制剂工艺技术建模与仿真 - 粒子技术视角

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Crystalline organic nanoparticles and their amorphous equivalents (ONP) have the potential to become a next-generation formulation technology for dissolution-rate limited biopharmaceutical classification system (BCS) class IIa molecules if the following requisites are met: (i) a quantitative understanding of the bioavailability enhancement benefit versus established formulation technologies and a reliable track record of successful case studies are available; (ii) efficient experimentation workflows with a minimum amount of active ingredient and a high degree of digitalization via, e.g., automation and computer-based experimentation planning are implemented; (iii) the scalability of the nanoparticle-based oral delivery formulation technology from the lab to manufacturing is ensured. Modeling and simulation approaches informed by the pharmaceutical material science paradigm can help to meet these requisites, especially if the entire value chain from formulation to oral delivery is covered. Any comprehensive digitalization of drug formulation requires combining pharmaceutical materials science with the adequate formulation and process technologies on the one hand and quantitative pharmacokinetics and drug administration dynamics in the human body on the other hand. Models for the technical realization of the drug production and the distribution of the pharmaceutical compound in the human body are coupled via the central objective, namely bioavailability. The underlying challenges can only be addressed by hierarchical approaches for property and process design. The tools for multiscale modeling of the here-considered particle processes (e.g., by coupled computational fluid dynamics, population balance models, Noyes–Whitney dissolution kinetics) and physiologically based absorption modeling are available. Significant advances are being made in enhancing the bioavailability of hydrophobic compounds by applying innovative solutions. As examples, the predictive modeling of anti-solvent precipitation is presented, and options for the model development of comminution processes are discussed.
机译:结晶有机纳米颗粒及其无定形当量(ONP)有可能成为溶解速率限制生物制药分类系统(BCS)类IIA分子的下一代制剂技术,如果满足以下必要条件:(i)对其的定量理解生物利用度增强效益与成熟的配方技术和可靠的成功案例研究记录可用; (ii)通过实施最小的活性成分和高度数字化的有效实验工作流程,例如,实施自动化和基于计算机的实验规划; (iii)确保了基于纳米粒子的口腔递送制剂技术从实验室到制造的可扩展性。由制药材料科学范式通知的建模和仿真方法可以帮助满足这些必需品,特别是如果将整个价值链从制定到口头递送。药物制剂的任何全面数字化都需要将药物科学与适当的配方和工艺技术相结合,另一方面是人体的定量药代动力学和药物管理动力学。用于技术实现的模型和人体中药物化合物的分布通过中心目标偶联,即生物利用度。潜在的挑战只能通过财产和流程设计的分层方法来解决。可获得来自于此考虑的粒子过程的多尺度建模的工具(例如,通过耦合计算流体动力学,人口平衡模型,Noyes-Whitney溶出动力学)和生理基础的吸收建模。通过应用创新解决方案,正在提高疏水化合物的生物利用度进行显着进展。作为实施例,讨论了抗溶剂沉淀的预测建模,并讨论了粉碎过程的模型开发的选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号